5 ms·

This vaccine is an inactive host virus whose payload has been replaced by the coronavirus "spike". It has always been a worry that the body will generate immuni

This vaccine is an inactive host virus whose payload has been replaced by the coronavirus "spike". It has always been a worry that the body will generate immunity to the host virus and thus make the vaccine less effective. That is a likely explanation for the first-full-dose regimen being less effective.

aquadrop 6y ago
Shouldn't it warrant a research if even smaller dose has even higher efficiency?
- pessimist 6y ago
  Yes. But clinical trials are expensive ($100m plus) and time consuming.
  - _Gyan_ 6y ago
    If both regimens underwent Phase 2 testing, there should be data on comparative immunogenicity.